@article{fdi:010090459,
  title = {{P}revention of mother-to-child transmission of {HIV} at the second immunization visit : a cross-sectional study, {B}urkina {F}aso},
  author = {{S}akana, {B}. {L}eticia {D}. and {M}ennecier, {A}. and {F}ao, {P}. and {T}assembedo, {S}. and {M}oles, {J}.-{P}. and {K}ania, {D}. and {T}aofiki, {A}. {O}. and {K}adeba, {F}. {E}. and {D}iallo, {I}. and {E}ymard-{D}uvernay, {S}abrina and {D}'{O}ttavi, {M}. and {M}eda, {N}. and {M}osqueira, {B}. and {V}an de {P}erre, {P}. and {N}agot, {N}. and {ANRS} 12388 {PREVENIR}-{PEV} {S}tudy {G}roup,},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective : {T}o evaluate the performance of the cascade of activities for prevention of mother-to-child transmission ({PMTCT}) of human immunodeficiency virus ({HIV}) at the second immunization visit in {B}urkina {F}aso. {M}ethods : {I}n a cross-sectional study, we recruited mothers attending the second immunization visit for their infant in 20 health centres of {B}obo-{D}ioulasso city, {B}urkina {F}aso over 12 months (2019-2020). {W}e administered a short questionnaire to 14 176 mothers and performed {HIV} serological tests on mothers who had not been tested in the last 3 months. {A}ll mothers were asked about their attendance for antenatal care and {HIV} rapid testing. {HIV}-infected mothers were also asked about the timing of their {HIV} diagnosis, antiretroviral therapy, pre-exposure prophylaxis initiation at birth and infant diagnosis of {HIV}. {F}indings {O}f 14 136 respondents, 13 738 (97.2%) had at least one {HIV} serological test in their lifetime. {O}f 13 078 mothers who were never tested or were {HIV}-negative, 12 454 (95.2%) were tested during or after their last pregnancy. {A}mong {HIV}-infected mothers already aware of their status, 110/111 (99.1%) women were on antiretroviral therapy. {A}mong {HIV}-exposed infants, 84/101 (83.2%) babies received 6 weeks of antiretroviral prophylaxis at birth and 58/110 (52.7%) had a blood sample collected for early infant diagnosis. {O}nly two mothers received their child's test results at the time of the second immunization visit. {F}our mothers were newly diagnosed as {HIV}-positive during the study. {C}onclusion : {C}ollecting data at the second immunization visit, a visit rarely missed by mothers, could be useful for identifying gaps in the {PMTCT} cascade in settings where mothers are difficult to reach, such as in low-income countries with intermediate or low {HIV} prevalence.},
  keywords = {{BURKINA} {FASO}},
  booktitle = {},
  journal = {{B}ulletin of the {W}orld {H}ealth {O}rganization},
  volume = {100},
  numero = {12},
  pages = {769--776},
  ISSN = {0042-9686},
  year = {2022},
  DOI = {10.2471/blt.22.288522},
  URL = {https://www.documentation.ird.fr/hor/fdi:010090459},
}